Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHBO1901 adjuvant GC versus GS after curative resection for biliary tract cancer
jRCTs051190040Phase 2Completed
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, cisplatin and tegafur in biliary cancer (2 arms). Primary endpoint: 2-year recurrence-free survival rate. Started Aug 2019; status: completed.
02
Drugs
gemcitabinecisplatintegafur
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs051190040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190040.